{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "A",
                    "alt": "P",
                    "position": "30"
                },
                "variant_string_id": "SNCA A30P"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "In Parkinson disease (PD), there is substantial loss of dopaminergic neurons in the substantia nigra pars compacta and presence of Lewy bodies containing aggregated proteins. Alpha - synuclein (a - synuclein) aggregation is a major event in the development of Lewy body pathology. Familial forms of PD have been linked to mutations in the gene encoding a - synuclein, such as A30P.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly defines the disease mechanism of PD, including the role of a - synuclein aggregation and the association of the A30P mutation in familial PD.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study uses assays like a - synuclein aggregation assay, proteasomal degradation assay, and cell survival assay. These assays are relevant as they model the processes of a - synuclein aggregation, degradation (which is related to its accumulation and aggregation), and the impact on cell survival, all of which are relevant to the PD disease mechanism.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis related to a - synuclein aggregation and its consequences in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The materials and methods section does not clearly state that both normal/negative/wild - type and abnormal/positive/null controls were used, nor does it explicitly mention that multiple replicates were used for all experiments.",
                    "judgment": "No",
                    "reasoning": "Since the paper does not clearly meet both criteria of using both types of controls and explicitly stating multiple replicates, we proceed to sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Step 3b"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The assays used, such as the a - synuclein aggregation assay, proteasomal degradation assay, and cell survival assay, are not described as broadly accepted historically, previously validated in other studies (no citations for validation), or provided as commercial kits.",
                    "judgment": "No",
                    "reasoning": "As none of the conditions for an accepted/validated assay are met, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "The A30P variant was studied in the context of PD - related a - synuclein processes. However, the assays did not meet the criteria for using PS3/BS3 as basic controls and replicates were not clearly established, and the assays were not shown to be accepted/validated."
        },
        {
            "variant_id": {
                "Gene": "SNCA",
                "Protein_Change": {
                    "ref": "A",
                    "alt": "T",
                    "position": "53"
                },
                "variant_string_id": "SNCA A53T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "In Parkinson disease (PD), there is substantial loss of dopaminergic neurons in the substantia nigra pars compacta and presence of Lewy bodies containing aggregated proteins. Alpha - synuclein (a - synuclein) aggregation is a major event in the development of Lewy body pathology. Familial forms of PD have been linked to mutations in the gene encoding a - synuclein, such as A53T.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly defines the disease mechanism of PD, including the role of a - synuclein aggregation and the association of the A53T mutation in familial PD.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study uses assays like a - synuclein aggregation assay, proteasomal degradation assay, and cell survival assay. These assays are relevant as they model the processes of a - synuclein aggregation, degradation (which is related to its accumulation and aggregation), and the impact on cell survival, all of which are relevant to the PD disease mechanism.",
                    "judgment": "Yes",
                    "reasoning": "The general classes of assays effectively model the disease pathogenesis related to a - synuclein aggregation and its consequences in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The materials and methods section does not clearly state that both normal/negative/wild - type and abnormal/positive/null controls were used, nor does it explicitly mention that multiple replicates were used for all experiments.",
                    "judgment": "No",
                    "reasoning": "Since the paper does not clearly meet both criteria of using both types of controls and explicitly stating multiple replicates, we proceed to sub - step 3b.",
                    "next_step_or_outcome": "Proceed to Step 3b"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
                    "extracted_paper_info": "The assays used, such as the a - synuclein aggregation assay, proteasomal degradation assay, and cell survival assay, are not described as broadly accepted historically, previously validated in other studies (no citations for validation), or provided as commercial kits.",
                    "judgment": "No",
                    "reasoning": "As none of the conditions for an accepted/validated assay are met, we do not use PS3/BS3.",
                    "next_step_or_outcome": "Do not use PS3/BS3"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "N/A"
            },
            "overall_conclusion": "The A53T variant was studied in the context of PD - related a - synuclein processes. However, the assays did not meet the criteria for using PS3/BS3 as basic controls and replicates were not clearly established, and the assays were not shown to be accepted/validated."
        }
    ]
}